Search for a trial | Research with human participants

1 results

A 52-week treatment, multicenter, randomized, doubleblind,
double dummy, placebo-controlled, parallel-group
study to assess the efficacy, safety and tolerability of
indacaterol (300 & 600 µg o.d.) in patients with chronic
obstructive pulmonary disease, using formoterol (12 µg
b.i.d.) as an active control

Approved WMORecruitment stopped

To assess indacaterol (300 and 600 ug once daily via SDDPI) superiority in patients with COPD as compared to placebo with respect to 24 h post dose (through) FEV1 after 12 weeks of treatment.